A trial of intepirdine was halted after the drug appeared to worsen cognition and motor control in patients with dementia with Lewy bodies. "Based on the totality of intepirdine data to date, there is no evidence to support its further development," said David Hung, chief executive of Swiss biotech Axovant, which developed the treatment.
Lewy body dementia drug trial halted in face of negative results
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.